Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GeNeuro SA

This article was originally published in Start Up

Executive Summary

Swiss start-up GeNeuro SA aims at an MS cure. The company licensed technology from French infectious-disease specialist bioMérieux SA, whose studies showed the presence of the MS-associated retrovirus (a member of the HERV-W family) may be a major triggering and aggravating factor in MS. GeNeuro's novel approach primarily focuses on the development of therapeutic monoclonal antibodies, which will target and neutralize the pathogenic MSRV/HERV-W proteins and thereby, in theory, prevent the initiation of the inflammatory and autoimmune cascades induced by these proteins in MS.

You may also be interested in...



GeNeuro, Servier Aim To Develop First Drug Addressing Causal MS Factor

Servier of France will progress Swiss biotech GeNeuro’s monoclonal antibody through Phase III trials aimed at the MSRV-Env protein which, if successful, could transform how multiple sclerosis is treated.

Receptos Inc.

Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.

Emerging MS Treatments: Reading the Gilenya Tea Leaves

The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel